GT Biopharma Statistics
Total Valuation
GT Biopharma has a market cap or net worth of $6.57 million. The enterprise value is -$2.52 million.
| Market Cap | 6.57M |
| Enterprise Value | -2.52M |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GT Biopharma has 2.23 million shares outstanding. The number of shares has increased by 22.54% in one year.
| Shares Outstanding | 2.23M |
| Shares Change (YoY) | +22.54% |
| Shares Change (QoQ) | +24.00% |
| Owned by Insiders (%) | 7.14% |
| Owned by Institutions (%) | 65.88% |
| Float | 1.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.22 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.47
| Current Ratio | 2.47 |
| Quick Ratio | 2.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -131.48% and return on invested capital (ROIC) is -95.50%.
| Return on Equity (ROE) | -131.48% |
| Return on Assets (ROA) | -60.59% |
| Return on Capital (ROIC) | -95.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.68M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.22% in the last 52 weeks. The beta is 0.62, so GT Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -60.22% |
| 50-Day Moving Average | 2.27 |
| 200-Day Moving Average | 3.41 |
| Relative Strength Index (RSI) | 63.82 |
| Average Volume (20 Days) | 24,106 |
Short Selling Information
The latest short interest is 10,375, so 0.46% of the outstanding shares have been sold short.
| Short Interest | 10,375 |
| Short Previous Month | 5,017 |
| Short % of Shares Out | 0.46% |
| Short % of Float | 0.62% |
| Short Ratio (days to cover) | 0.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.29M |
| Pretax Income | -9.64M |
| Net Income | -11.35M |
| EBITDA | n/a |
| EBIT | -13.29M |
| Earnings Per Share (EPS) | -$7.77 |
Balance Sheet
| Cash & Cash Equivalents | 9.25M |
| Total Debt | n/a |
| Net Cash | 9.25M |
| Net Cash Per Share | $4.14 |
| Equity (Book Value) | 5.51M |
| Book Value Per Share | 2.46 |
| Working Capital | 5.51M |
Cash Flow
| Operating Cash Flow | -11.71M |
| Capital Expenditures | n/a |
| Free Cash Flow | -11.71M |
| FCF Per Share | -$5.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GT Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.54% |
| Shareholder Yield | -22.54% |
| Earnings Yield | -168.82% |
| FCF Yield | -174.12% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 5, 2024. It was a reverse split with a ratio of 0.0333333:1.
| Last Split Date | Feb 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0333333:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |